Vascular Dementia Clinical Trial
Official title:
Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia:A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension
Verified date | May 2014 |
Source | Shineway Pharmaceutical Co.,Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). The study hypothesis is that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to determine the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.
Status | Unknown status |
Enrollment | 372 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - 40 years old or above, gender is not limited; - Education=primary-school; - Dementia diagnosed according to Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV) criteria; - Probable VaD diagnosed by the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences(NINDS-AIREN) criteria; - Modified Hachinski ischemic scale(MHIS) total score=4; - Evidence of ischemic cerebrovascular disease on magnetic resonance imaging (MRI)and /or CT (corresponding with the imaging criteria of NINDS-AIREN) - Mild-to-moderate dementia defined by MMSE score between 10 and 26, CDR score between 1 and 2, both inclusive - Modified Hachinski ischemic scale(MHIS) total score=4; - Hamilton depression scale (HAMD) total score=17; - The patients agree to participate in the study and able to understand informed consent as well as signing it. In cases where patients are unable to do so, carer's consent will be obtained as proxy; - There are carers accompanying patients at least 4 days a week and can accompany patients to participate in each visit. Exclusion Criteria: - Dementia caused by other brain diseases except VaD (e.g. Alzheimer's disease, Lewy body dementia, frontotemporal dementia, Parkinson's disease, demyelinated disease of the central nervous system, tumour, hydrocephalus, head injury, central nervous system infection including syphilis, acquired immune deficiency syndrome, etc.); - The patient who can not complete examination because of severe brain or nerve function loss, such as convenient hand hemiplegia, all sorts of aphasia and audio-visual obstacles, etc; - The presence of abnormal laboratory parameters: Hemoglobin (Hb) and platelet (Plt)less than the lower limit; activated partial thromboplastin time (APTT) beyond the normal value more than 10 seconds, prothrombin time (PT) beyond the normal value more than 3 seconds; creatinine (Cr) more than 1.5 times the upper limit value; alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphates (ALP), ?-glutamyl transferase (?-GT) more than 2 times the upper limit of normal, total bilirubin (TBiL) more than 1.5 times the upper limit of normal; - Nutrition metabolic diseases and endocrine system lesions such as thyroid disease, parathyroid diseases,and deficiency of vitamins or other elements; - Severe circulatory, respiratory, urinary, digestive, hematopoietic system diseases (such as unstable angina, incontrollable asthma, active bleeding, etc.) and cancer; - Severe mental illness (such as depression, schizophrenia) and epilepsy; - Gastrointestinal disorders that affect drug absorption, distribution, and metabolism; - Alcohol and drug abuse; - Patients who are using and cannot stop the following drugs including Chinese herba preparation containing ginseng, ginkgo leaf or any component of the saffron; medications that may affect cognitive functioning, such as donepezil, rivastigmine, huperzine A, memantine, nimodipine; etc.; - Known to be allergic to the composition of SaiLuoTong; - Pregnancy or breast-feeding women; - New strokes within 3 months before baseline - Had participated in other clinical trials before this study 3 months prior to this study. |
Country | Name | City | State |
---|---|---|---|
China | The Central Hospital of Baotou | Baotou city | Inner Mongolia |
China | Beijing Friendship Hospital of Capital Medical University | Beijing | Beijing |
China | Dongzhimen Hospital affiliated to Beijing University of Chinese Traditional Medicine | Beijing | Beijing |
China | Xuan Wu Hospital of Capital Medical University | Beijing city | Beijing |
China | The First Hospital of Jilin University | Changchun | Jilin |
China | The Hospital of Traditional Chinese and Western Medicine of Jilin Province | Changchun | Jilin |
China | The First Hospital of Hunan University of Chinese Traditional Medicine | Changsha | Hunan |
China | The Affiliated Hospital of Chengdu Chinese Traditional Medicine | Chengdu | Sichuan |
China | The First people's Hospital of Chenzhou | Chenzhou | Hunan |
China | Southern Hospital of Southern Medical | Guangzhou | Guangdong |
China | The Chinese Traditional Medical Hospital of Guangdong Province | Guangzhou city | Guangdong |
China | The First Hospital of Zhejiang University | Hangzhou | Zhejiang |
China | Chinese Traditional Medical Hospital of Jiangsu Province | Nanjing | Jiangsu |
China | The Zhongda Hospital of Southeast University | Nanjing | Jiangsu |
China | The Shuguang Hospital of Shanghai University of Chinese Traditional Medicine | Shanghai | Shanghai |
China | The First Hospital of Tianjin University of Chinese Traditional Medicine | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Shineway Pharmaceutical Co.,Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | V-ADAS-cog | The V-ADAS-cog comprises the ADAS-cog plus the Maze and Number Cancellation test to specifically assess executive function. | weeks 0, 13, 26, 39, and 52 | |
Primary | ADCS-CGIC | The ADCS-CGIC involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. | weeks 0, 13, 26, 39, and 52 | |
Secondary | ADCS - ADL | An inventory to assess the patient's ability to do basic activities of daily living and instrumental activities of daily living. | weeks 0, 26, and 52 | |
Secondary | MMSE | The MMSE is a global test of cognitive function, for which the total score ranges from 0 to 30, with higher scores indicating lesser severity. | screening, weeks 0, 26, and 52 | |
Secondary | CDR scale | The CDR is a numeric scale used to quantify the severity of symptoms of dementia (i.e. its 'stage'). | screening, weeks 0, 26, and 52 | |
Secondary | CLOX | It was designed to elicit executive impairment and to discriminate it from non-executive constructional failure. | weeks 0, 26, and 52 | |
Secondary | C-EXIT25 | The C-EXIT25 is a measure of executive function based on a 15-min interview addressing 25 items related to executive cognition. | weeks 0, 26, and 52 | |
Secondary | NPI | The NPI is used to assess neuropsychiatric symptoms. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions. | weeks 0, 26, and 52 | |
Secondary | CDR-sb | CDR-sb is the sum of boxes of CDR, with higher scores indicating severer degree of impairment. | weeks 0, 26, and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Completed |
NCT01761227 -
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
|
Phase 2 | |
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT00165763 -
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
|
Phase 4 | |
Completed |
NCT00621647 -
Seroquel- Agitation Associated With Dementia
|
Phase 3 | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Recruiting |
NCT03275363 -
The University of Hong Kong Neurocognitive Disorder Cohort
|
N/A | |
Active, not recruiting |
NCT03804229 -
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
|
Phase 3 | |
Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
Completed |
NCT02453932 -
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
|
Phase 3 | |
Completed |
NCT00947531 -
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
|
Phase 4 | |
Not yet recruiting |
NCT03702543 -
Managing Vascular Dementia Risk Factors With SymTrend
|
Phase 1 | |
Enrolling by invitation |
NCT02147652 -
Personalized Music Therapy and Agitation in Dementia
|
N/A | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|
||
Recruiting |
NCT06034509 -
Cognitive and Vascular Functioning Following TBI
|
||
Recruiting |
NCT05921266 -
Urolithin A Supplementation in Middle-aged Adults With Obesity
|
N/A | |
Completed |
NCT01465360 -
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
|
N/A |